Pharmaceuticals, Biotechnology & Life Sciences

Trevi Therapeutics (TRVI) trades under its 200‑day MA at $12.61, with a strong $250M cash buffer and upcoming Phase‑2a data for IPF in Q3 2027. Watch the next milestone for a potential upside.

Stock update: Kwang Dong Pharmaceutical’s shares slipped 0.6%, trading at KRW 6,450 amid a KRW 327.5 billion market cap. Key 200‑day SMA: KRW 6,934.8.

Yunnan Baiyao shares steady at CNY 53.61, 5% up month‑to‑date, amid stable 200‑day trend and growing pharma portfolio, promising health‑care growth.

Omniab (OABI) dips 2.51% amid market volatility—still trading above its 200‑day MA, with a bright antibody discovery pipeline poised for rebound. Read why investors should watch.

ERASCA stock rises 2.49% as Phase II lung‑cancer trial data sparks investor confidence, positioning the company closer to its $24.28 52‑week peak.

Rallybio (RLYB) climbs 1.46 % to $16.64 – a biotech firm eyeing rare‑disease therapies with a market cap of $88.4 M and a strong 52‑week range. Click for details.

Corbus Holdi (CRBP) fell 45.6% last month, trading at $4.05 with 1.5M volume. Discover key metrics, tech indicators, and compare with peers.

Hanall Biopharma slides as investors doubt its research‑driven pipeline, questioning whether its biotech breakthroughs can translate into revenue.

Bridgebio Oncology Therapeut shares fall 6.7% as investors await new clinical data and partnership prospects, amid a broader biotech market dip.

Charles River Laboratories stock rises 1.68% to $345.37 as its 17.3% 30‑day gain highlights growing biotech research demand – see key metrics, related stocks, and upcoming SoFi earnings.